

# Irritable Bowel Syndrome and Functional Dyspepsia: Different Ends of the Same Spectrum of Intestinal Barrier Dysfunction?

Citation for published version (APA):

Keszthelyi, D. (2021). Irritable Bowel Syndrome and Functional Dyspepsia: Different Ends of the Same Spectrum of Intestinal Barrier Dysfunction? *American Journal of Gastroenterology*, 116(7), 1556-1556. <https://doi.org/10.14309/ajg.0000000000001174>

**Document status and date:**

Published: 01/07/2021

**DOI:**

[10.14309/ajg.0000000000001174](https://doi.org/10.14309/ajg.0000000000001174)

**Document Version:**

Publisher's PDF, also known as Version of record

**Document license:**

Taverne

**Please check the document version of this publication:**

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

**Take down policy**

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

## REFERENCES

- Ozdogan E, Doganay L, Can D, et al. Disease course and treatment response of eosinophilic gastrointestinal diseases in children with liver transplantation: Long-term follow-up. *Am J Gastroenterol* 2021;116(1):188–97.
- Philpott H, Dellon ES. Eosinophilic GI disorders after transplantation are a unique transient entity. *Am J Gastroenterol* 2021; 116(7):1554–5.
- Philpott H, Dellon ES. Solid organ transplantation is not a risk factor for eosinophilic oesophagitis: A review of 13,792 transplants performed on a predominantly adult population in North Carolina: 359. *Am J Gastroenterol* 2017;112:S193.
- Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. *J Allergy Clin Immunol* 2009; 124(6):1326–32.e6.
- Czarnowicki T, He H, Canter T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. *J Allergy Clin Immunol* 2020;145(1):215–28.
- Hosakoppal SS, Bryce PJ. Transplant-acquired food allergy: Current perspectives. *J Asthma Allergy* 2017;10:307–15.
- Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. *Gastroenterology* 2018;154(2):319–32.e3.

<sup>1</sup>Pediatric Gastroenterology, Hepatology, and Nutrition Liver Transplantation Center, Koc University School of Medicine, Istanbul, Turkey; <sup>2</sup>Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey.

**Correspondence:** Cigdem Arkan, MD. E-mail: cigdemarikanmd@yahoo.com.

# Irritable Bowel Syndrome and Functional Dyspepsia: Different Ends of the Same Spectrum of Intestinal Barrier Dysfunction?

Daniel Keszthelyi, MD, PhD<sup>1</sup>

*Am J Gastroenterol* 2021;116:1556. <https://doi.org/10.14309/ajg.000000000001174>

I read with interest the article from Nojkov et al. (1) describing the role of duodenal barrier dysfunction as an important underlying mechanism for the development of functional dyspepsia (FD).

More recently, the focus in FD has also increasingly shifted to the small intestine (more specifically the duodenum), in which the intestinal barrier dysfunction and the influx of inflammatory cells, in particular eosinophils and mast cells, have been indicated to being key players. The study by Nojkov et al. (1) elegantly demonstrates this using a combination of confocal laser endomicroscopy and *ex vivo* techniques and complements work performed previously by others (in particular the Tack and Talley groups) on the subject.

Small intestinal barrier function has also received considerable attention as a potential pathomechanism in irritable bowel syndrome (IBS) (2), and this in fact predates similar hypotheses with regards to FD. More interestingly, other studies in patients with IBS using confocal laser endomicroscopy have demonstrated largely similar barrier defects in the distal duodenum (3), terminal ileum (4) and colon (5) to those observed in the Nojkov study in FD patients.

Considering the substantial symptomatic overlap between IBS and FD, one wonders whether these disorders are in fact part of the same underlying problem, i.e., intestinal barrier dysfunction. This overlap is further highlighted by the fact that in one of the landmark studies on FD and intestinal barrier dysfunction, 9 of 15 (60%) FD patients also had comorbid IBS (6).

The magnitude and the anatomical distribution (duodenum to colon) of this disturbance would then determine whether the symptoms are more skewed toward primarily upper or lower gastrointestinal phenomena. Importantly, abnormal sensations, in particular pain and discomfort, arising from the gastrointestinal tract are common denominators for both disorders, and the influence of the inflammatory infiltrate on afferent signaling function provides the rationale behind this hypothesis. In this sense, an overarching concept of barrier dysfunction is not necessarily at odds with the new Rome IV concept of interpreting these as disorders of the gut-brain interaction. On the contrary, it tributes to the need for identifying structural changes that allow us to move away from the negative connotations associated with a “functional” disorder.

What, however, remains a challenge is identifying the ways to improve or reinforce barrier function. Although the

concept has been around for quite some time, we have yet to find effective ways to correct these defects. A phase III study currently ongoing in celiac disease, using larazotide acetate, a synthetic antagonist to zonulin, an endogenous protein that modulates intestinal tight junctions, might provide important leads to further research in other areas, such as FD or IBS. The solution need not necessarily be pharmacological because previous studies have pointed to specific food-derived substances driving barrier dysfunction (3). Either way, embracing the concept of leaky gut provides a unique opportunity to refining therapies for a large group of patients.

## CONFLICTS OF INTEREST

**Guarantor of the article:** Daniel Keszthelyi, MD, PhD.

**Specific author contributions:** D.K.: wrote the article.

**Financial support:** None to report.

**Potential competing interests:** D.K. has received grants from Allergan, Grunenthal, Will Pharma, ZonMw, Horizon 2020, MLDS, and UEG; outside of submitted work.

## REFERENCES

- Nojkov B, Zhou SY, Dolan RD, et al. Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and *ex vivo* mucosa analysis. *Am J Gastroenterol* 2020;115(11):1891–901.
- Mujagic Z, Jonkers D, Masclee AAM, et al. A key role for the small bowel in irritable bowel syndrome pathophysiology: Time to refocus? *Clin Gastroenterol Hepatol* 2021;19(2):409–10.
- Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. *Gastroenterology* 2014;147:1012–20.e4.
- Turcotte JF, Kao D, Mah SJ, et al. Breaks in the wall: Increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). *Gastrointest Endosc* 2013;77:624–30.
- Robles-Medrandia C, Oleas R, Valero M, et al. Confocal laser endomicroscopy detects colonic inflammation in patients with irritable bowel syndrome: A prospective study. *Endosc Int Open* 2020;8:E550–7.
- Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. *Gut* 2014;63:262–71.

<sup>1</sup>Division of Gastroenterology-Hepatology, Department of Internal Medicine, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Center+, Maastricht, the Netherlands.

**Correspondence:** Daniel Keszthelyi, MD, PhD. E-mail: daniel.keszthelyi@maastrichtuniversity.nl.